Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01752543
Recruitment Status : Completed
First Posted : December 19, 2012
Last Update Posted : June 17, 2015
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Finn Gustafsson, Rigshospitalet, Denmark

Brief Summary:

The purpose of the present study is to evaluate the effects of a blockade of the vasopressin system and central hemodynamic system in heart failure (HF) patients during physical exercise. The significance of the vasopressin system during physical exercise is unclear. If vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to intervene against activation of the V1A-receptor might be expected to improve HF symptoms and possibly outcome.

The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz catheter. Echocardiography will be performed at rest and during submaximal working capacity before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo. Cardiac output will be measured by thermodilution. The exercise test will be performed at 50 % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The exercise test will be performed on a supine multistage bicycle.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Conivaptan Drug: Placebo (Dextrose) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients
Study Start Date : December 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Conivaptan
10 patients will be randomized to conivaptan treatment
Drug: Conivaptan
Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
Other Name: Vaprisol
Placebo Comparator: Dextrose
10 patients will receive placebo treatment (dextrose)
Drug: Placebo (Dextrose)
Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
Other Name: 5 % dextrose

Primary Outcome Measures :
  1. The joint endpoint of change in pulmonary capillary wedge pressure (PCWP) and cardiac output (CO) at the submaximal exercise intensity of 50 % of the maximal exercise capacity [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Cardiac index (CI) during submaximal exercise from rest to submaximal exercise [ Time Frame: 1 day ]
  2. Pulmonary and systemic vascular resistance from rest to submaximal exercise [ Time Frame: 1 day ]
  3. Left ventricular end diastolic diameter during exercise from rest to submaximal exercise [ Time Frame: 1 day ]
  4. The change in mean pulmonary artery pressure (mPAP) from rest to submaximal exercise [ Time Frame: 1 day ]
  5. The change in BNP, MR-ANP and copeptin from rest to submaximal exercise [ Time Frame: 1 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years
  • Left ventricular ejection fraction (LVEF) < 45 % on the baseline echocardiography.
  • Treatment with beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors for at least 1 month as tolerated
  • New York Heart Association (NYHA) Functional Class II-III
  • Given informed consent
  • Women, who have not yet entered menopause (defined as no menstrual bleeding in the last 12 months), will provide a negative urine HCG before entering the study

Exclusion Criteria:

  • Signs of symptomatic or ongoing myocardial ischemia
  • Known non-revascularized coronary disease
  • Presence of hypovolemic hyponatremia (P-Na+ <130 mmol/l and clinical signs of volume depletion or dehydration as judged by investigator).
  • Hypernatraemia (P-Na+) > 145 mmol/L
  • Chronic obstructive pulmonary disease (FEV1/FVC < 70 % and/or 30 % > FEV1 < 50 %)
  • Supine systolic blood pressure < 85 mmHg
  • Significant orthostatic hypotension
  • Standing blood pressure < 80 mmHg or a blood pressure drop > 20 mmHg when changing from a supine to a standing position
  • Uncontrolled hypertension evaluated by the investigator
  • Uncontrolled cardiac arrhythmias evaluated by the investigator
  • Untreated serious hypothyroidism
  • Adrenal insufficiency
  • Poor echocardiographic window
  • Inability to perform exercise testing
  • Permanent atrial fibrillation or atrial fluttering
  • Planned coronary by-pass surgery
  • Moderate hepatic impairment (ALAT/ASAT > 3 UNL)
  • Presence of other diseases affecting treatment with conivaptan or the evaluation of safety as evaluated by the investigator
  • Severely decreased kidney function (eGFR < 20 mL/min)
  • Serum K+< 3.5 or > 5.5 mmol/L
  • Known conivaptan intolerability
  • Corn allergy
  • Dextrose Allergy
  • Treatment with potent CYP3A-inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir)
  • Treatment with arginine vasopressin, oxytocin, desmopressin and other medications for the treatment of hyponatremia (lithium salts, urea and demeclocycline)
  • Warfarin treatment
  • Presence of infection or active bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01752543

Department of Cardiology, Copenhagen University Hospital, Rigshospital
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Finn Gustafsson
Rigshospitalet, Denmark
Principal Investigator: Louise Balling, MD Rigshospitalet, Denmark
Principal Investigator: Finn Gustafsson, MD, PhD, DMSci Rigshospitalet, Denmark

Responsible Party: Finn Gustafsson, Staff Cardiologist, MD, Phd, DMSci, Rigshospitalet, Denmark Identifier: NCT01752543     History of Changes
Other Study ID Numbers: H-3-2012-139
First Posted: December 19, 2012    Key Record Dates
Last Update Posted: June 17, 2015
Last Verified: June 2015

Keywords provided by Finn Gustafsson, Rigshospitalet, Denmark:
Exercise capacity

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Arginine Vasopressin
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action